A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy.

Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OAK
  • Sponsors Roche
  • Most Recent Events

    • 18 Apr 2018 Results evaluating C-reactive protein (CRP) in clinical trials with atezolizumab (POPLAR and OAK trial) presented at the 109th Annual Meeting of the American Association for Cancer Research
    • 19 Jan 2018 According to a Chugai Pharmaceutical media release, Chugai Pharmaceutical announced that it has obtained approval of its humanized anti-PD-L1 monoclonal antibody TECENTRIQ intravenous infusion 1200mg from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of unresectable advanced or recurrent non-small cell lung cancer (NSCLC).
    • 18 Oct 2017 Results of long term survival in patients with non small cell lung cancer, presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top